Accredited Educational Activities

CLICK ON STATES TO SEE LIVE ACTIVITIES

BOOTH TOUR

Jul
25
Sat
Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention
Jul 25 2020 @ 1:00 am – Feb 19 2022 @ 2:00 am

Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention

View Activity

FACULTY

Neil M. Bressler, MD
James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

Participation by Dr. Neil Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the
Johns Hopkins Hospital, or the Johns Hopkins Health System nor by JAMA Ophthalmology.

 


PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with early intervention in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) without center-involved macular edema, which can have a profound impact on vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to nAMD, DME and DR management through utilization of clinical trial data, guideline-based treatment approaches and patient-specific factors – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that early vs delayed intervention can have on vision-related quality of life.
  • You will also be immersed in dynamic animations utilizing virtual reality and whiteboard platforms to memorably highlight key points related to how visual acuity is affected by intervention at different disease stages or treatment delay, as well as the impact of anti-vascular endothelial growth factor (anti-VEGF) therapy on the pathophysiologic defects associated with nAMD, DME and DR.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, and managed care professionals who manage patients with nAMD, DME, and DR in the absence of center-involved DME.


LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Evaluate clinical trial evidence on the optimization of monitoring, treatment dosing, and the association of early intervention on visual acuity outcomes in neovascular AMD (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) in the absence of center-involved DME
  • Assess the impact of treatments for nAMD, DME, and DR in the absence of center-involved DME on patients’ patient-reported vision-related quality of life
  • How to develop treatment plans for the management of nAMD, DME, and DR in the absence of center-involved DME that incorporate evidence from clinical trials, guideline recommendations, and patient-specific factors

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with nAMD, DME, and DR in the absence of center-involved DME.
Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Neil Bressler, MD receives grants to his institution for his research efforts from Bayer, Biogen, Novartis, Roche/Genentech, and Samsung Bioepis. He also serves as Chair of the National Eye Institute Data and Safety Monitoring Committee for Intramural Trials for the Emmes Company. He is also Editor in Chief of JAMA Ophthalmology.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse.
The reviewer has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Coordinator, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the enduring activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

RELEASE DATE: February 19, 2021

EXPIRATION DATE: February 19, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
27
Mon
Saving Sight in AMD: Key Concepts in Pathogenesis, Treatment Options and Management
Jul 27 2020 @ 12:00 am – Jul 27 2021 @ 11:45 pm

Saving Sight in AMD: Key Concepts in Pathogenesis, Treatment Options and Management

 

VIEW ACTIVITY

FACULTY

Steven Ferrucci, OD, FAAO
Chief of Optometry
Sepulveda VA Medical Center, Los Angeles, CA
Professor
Southern California College of Optometry at Marshall B. Ketchum University Fullerton, CA

PROGRAM OVERVIEW

This online activity is focused on the management of patients with age-related macular degeneration (AMD).

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in patients who have or are at risk for developing AMD
  • Describe the progressive visual changes that can be experienced by those who have or are at risk for and those that have been treated for AMD, thereby emphasizing the importance of proper eye care
  • Establish collaborative strategies that promote team-based communication and patient continuity of care to provide appropriate eye care delivery for patients who have or are at risk for developing AMD
  • Define the pathogenic changes observed with AMD which would be best managed by team-based approaches for appropriate eye care delivery
  • Evaluate the efficacy and safety of currently available treatments, including agents that target the VEGF pathway, used to manage patients with AMD

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based live activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.
Credits: 1.0 ANCC Contact Hour

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Steven Ferrucci, OD, FAAO, is on the speakers’ bureau/advisory board member for Alcon, CenterVue, Genentech, MacuLogix, Optovue, Regeneron, ScienceBased Health, and Visible Genomics.

Staff, Planners, and Managers
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests.

CME Content Review
The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse. The reviewer has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: July 27, 2020

EXPIRATION DATE: July 27, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

VIEW ACTIVITY

Jul
30
Thu
No Eyes Left Behind: Diabetic Retinopathy Clinical Essentials Related to Prevalence and Risk, Pathobiology, Detection and Treatment
Jul 30 2020 @ 12:00 am – Jul 30 2021 @ 11:45 pm

No Eyes Left Behind: Diabetic Retinopathy
Clinical Essentials Related to Prevalence and Risk, Pathobiology, Detection and Treatment

VIEW ACTIVITY

FACULTY

A. Paul Chous, MA, OD, FAAO
Chief of Optometry
Chous Eye Care Associates
Tacoma, WA
Adjunct Instructor
Nova Southeastern University College of Optometry
Optometrist and Diabetes Educator
Chous Eye Care Associates
Tacoma, WA

PROGRAM OVERVIEW

This online activity is focused on the management of patients with diabetic retinopathy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in patients who have or are at risk for developing diabetic retinopathy (DR)
  • Describe the progressive visual changes that can be experienced by those who have or are at risk for and those who have been treated for DR, thereby emphasizing the importance of proper eye care
  • Establish collaborative strategies that promote team-based communication and patient continuity of care to provide appropriate eye-care delivery for patients who have or are at risk for developing DR
  • Define the pathogenic changes observed with DR that would be best managed by team-based approaches for appropriate eye-care delivery
  • Evaluate the efficacy and safety of currently available treatments, including panretinal photocoagulation (PRP) and agents that target the VEGF pathway, used to manage patients with DR

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based live activity for a maximum of 1.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the web-based live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with DR.
Credits: 1.25 ANCC Contact Hour(s).

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

A.Paul Chous, MA, OD, FAAO, has received royalties and consulting fees from EyePromise. He is on the speaker’s bureaus for EyePromise, Regeneron, Genentech, and Zeiss. Dr. Chous has received fees for Non-CME/CE Services Received Directly from Regeneron and Genentech.

Staff, Planners, and Managers
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse. The reviewer has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Melissa Johnson, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: July 30, 2020

EXPIRATION DATE: July 30, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

VIEW ACTIVITY

Aug
28
Fri
AMD 2020: Best Practices for Current Management and Future Directions
Aug 28 2020 @ 5:45 pm – Aug 28 2021 @ 6:45 pm

AMD 2020: Best Practices for Current Management and Future Directions

FACULTY


Allen C. Ho, MD, FACS
Wills Eye Hospital Attending Surgeon and Director of Retina Research
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlanta Retina

PROGRAM OVERVIEW

This online activity is focused on management of patients with age-related macular degeneration.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in AMD patients
  • Describe progressive visual changes experienced by AMD patients
  • Establish collaborative strategies that promote team-based communication and patient continuity of care
  • Define the pathogenic changes observed with AMD
  • Evaluate the efficacy and safety of currently available anti-VEGF AMD treatments and potential future treatments in clinical development

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.

Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Allen Ho discloses the following:
– He is a consultant/advisor for Adverum, Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, Asclepix, Beaver-Visitec International, BioTime, Chengdu Kanghong Biotechnology, Genentech, Graybug, Gyroscope, IRIDEX, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, Notal, ONL, Optovue, PanOptica, Regeneron and RegenXBio.
– He has received grants from Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, BioTime, Chengdu Kanghong Biotechnology, Genetech, Gemini, Graybug, Gyroscope, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, Lumithera, National Eye Institute, Novartis, Optovue, ProQR, Regeneron, RegenXBio and Sanofi.
– He has ownership in Covalent Medical, ONL and PanOptica.

The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff Planners and Managers
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit
participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: August 28, 2020

EXPIRATION DATE: August 28, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

 

 

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

Jun
23
Wed
AMD Grand Rounds (Speaker: David Brown, MD)
Jun 23 @ 3:00 pm – 4:00 pm

Confirmed Date
Wednesday, June 23

Time
3:00 – 4:00 PM ET

Location
Age Related Macular Degeneration Grand Rounds

Confirmed Speaker
David Brown, MD

Jun
30
Wed
Prescott, AZ (Speaker: David Brown, MD)
Jun 30 @ 11:00 am – 12:00 pm

Confirmed Date
Wednesday, June 30

Time
11:00 – 12:00 PM EDT

Location
Age Related Macular Degeneration Grand Rounds
Prescott, AZ

Confirmed Speaker
David Brown, MD

Jul
23
Fri
Saginaw, MI (Speaker: David Brown, MD)
Jul 23 @ 8:00 am – 9:00 am

Confirmed Date
Friday, July 23

Time
8:00 – 9:00 AM EDT

Location
Age Related Macular Degeneration Grand Rounds
Saginaw, MI

Confirmed Speaker
David Brown, MD

AMD GRAND ROUNDS

Jun
23
Wed
AMD Grand Rounds (Speaker: David Brown, MD)
Jun 23 @ 3:00 pm – 4:00 pm

Confirmed Date
Wednesday, June 23

Time
3:00 – 4:00 PM ET

Location
Age Related Macular Degeneration Grand Rounds

Confirmed Speaker
David Brown, MD

Jun
30
Wed
Prescott, AZ (Speaker: David Brown, MD)
Jun 30 @ 11:00 am – 12:00 pm

Confirmed Date
Wednesday, June 30

Time
11:00 – 12:00 PM EDT

Location
Age Related Macular Degeneration Grand Rounds
Prescott, AZ

Confirmed Speaker
David Brown, MD

Jul
23
Fri
Saginaw, MI (Speaker: David Brown, MD)
Jul 23 @ 8:00 am – 9:00 am

Confirmed Date
Friday, July 23

Time
8:00 – 9:00 AM EDT

Location
Age Related Macular Degeneration Grand Rounds
Saginaw, MI

Confirmed Speaker
David Brown, MD

ONLINE ACTIVITIES

Jul
25
Sat
Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention
Jul 25 2020 @ 1:00 am – Feb 19 2022 @ 2:00 am

Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention

View Activity

FACULTY

Neil M. Bressler, MD
James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

Participation by Dr. Neil Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the
Johns Hopkins Hospital, or the Johns Hopkins Health System nor by JAMA Ophthalmology.

 


PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with early intervention in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) without center-involved macular edema, which can have a profound impact on vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to nAMD, DME and DR management through utilization of clinical trial data, guideline-based treatment approaches and patient-specific factors – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that early vs delayed intervention can have on vision-related quality of life.
  • You will also be immersed in dynamic animations utilizing virtual reality and whiteboard platforms to memorably highlight key points related to how visual acuity is affected by intervention at different disease stages or treatment delay, as well as the impact of anti-vascular endothelial growth factor (anti-VEGF) therapy on the pathophysiologic defects associated with nAMD, DME and DR.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, and managed care professionals who manage patients with nAMD, DME, and DR in the absence of center-involved DME.


LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Evaluate clinical trial evidence on the optimization of monitoring, treatment dosing, and the association of early intervention on visual acuity outcomes in neovascular AMD (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) in the absence of center-involved DME
  • Assess the impact of treatments for nAMD, DME, and DR in the absence of center-involved DME on patients’ patient-reported vision-related quality of life
  • How to develop treatment plans for the management of nAMD, DME, and DR in the absence of center-involved DME that incorporate evidence from clinical trials, guideline recommendations, and patient-specific factors

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with nAMD, DME, and DR in the absence of center-involved DME.
Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Neil Bressler, MD receives grants to his institution for his research efforts from Bayer, Biogen, Novartis, Roche/Genentech, and Samsung Bioepis. He also serves as Chair of the National Eye Institute Data and Safety Monitoring Committee for Intramural Trials for the Emmes Company. He is also Editor in Chief of JAMA Ophthalmology.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse.
The reviewer has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Coordinator, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the enduring activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

RELEASE DATE: February 19, 2021

EXPIRATION DATE: February 19, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
27
Mon
Saving Sight in AMD: Key Concepts in Pathogenesis, Treatment Options and Management
Jul 27 2020 @ 12:00 am – Jul 27 2021 @ 11:45 pm

Saving Sight in AMD: Key Concepts in Pathogenesis, Treatment Options and Management

 

VIEW ACTIVITY

FACULTY

Steven Ferrucci, OD, FAAO
Chief of Optometry
Sepulveda VA Medical Center, Los Angeles, CA
Professor
Southern California College of Optometry at Marshall B. Ketchum University Fullerton, CA

PROGRAM OVERVIEW

This online activity is focused on the management of patients with age-related macular degeneration (AMD).

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in patients who have or are at risk for developing AMD
  • Describe the progressive visual changes that can be experienced by those who have or are at risk for and those that have been treated for AMD, thereby emphasizing the importance of proper eye care
  • Establish collaborative strategies that promote team-based communication and patient continuity of care to provide appropriate eye care delivery for patients who have or are at risk for developing AMD
  • Define the pathogenic changes observed with AMD which would be best managed by team-based approaches for appropriate eye care delivery
  • Evaluate the efficacy and safety of currently available treatments, including agents that target the VEGF pathway, used to manage patients with AMD

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based live activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.
Credits: 1.0 ANCC Contact Hour

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Steven Ferrucci, OD, FAAO, is on the speakers’ bureau/advisory board member for Alcon, CenterVue, Genentech, MacuLogix, Optovue, Regeneron, ScienceBased Health, and Visible Genomics.

Staff, Planners, and Managers
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests.

CME Content Review
The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse. The reviewer has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: July 27, 2020

EXPIRATION DATE: July 27, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

VIEW ACTIVITY

Aug
28
Fri
AMD 2020: Best Practices for Current Management and Future Directions
Aug 28 2020 @ 5:45 pm – Aug 28 2021 @ 6:45 pm

AMD 2020: Best Practices for Current Management and Future Directions

FACULTY


Allen C. Ho, MD, FACS
Wills Eye Hospital Attending Surgeon and Director of Retina Research
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlanta Retina

PROGRAM OVERVIEW

This online activity is focused on management of patients with age-related macular degeneration.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in AMD patients
  • Describe progressive visual changes experienced by AMD patients
  • Establish collaborative strategies that promote team-based communication and patient continuity of care
  • Define the pathogenic changes observed with AMD
  • Evaluate the efficacy and safety of currently available anti-VEGF AMD treatments and potential future treatments in clinical development

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.

Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Allen Ho discloses the following:
– He is a consultant/advisor for Adverum, Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, Asclepix, Beaver-Visitec International, BioTime, Chengdu Kanghong Biotechnology, Genentech, Graybug, Gyroscope, IRIDEX, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, Notal, ONL, Optovue, PanOptica, Regeneron and RegenXBio.
– He has received grants from Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, BioTime, Chengdu Kanghong Biotechnology, Genetech, Gemini, Graybug, Gyroscope, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, Lumithera, National Eye Institute, Novartis, Optovue, ProQR, Regeneron, RegenXBio and Sanofi.
– He has ownership in Covalent Medical, ONL and PanOptica.

The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff Planners and Managers
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit
participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: August 28, 2020

EXPIRATION DATE: August 28, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

 

 

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

Jul
25
Sat
Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention
Jul 25 2020 @ 1:00 am – Feb 19 2022 @ 2:00 am

Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention

View Activity

FACULTY

Neil M. Bressler, MD
James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

Participation by Dr. Neil Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the
Johns Hopkins Hospital, or the Johns Hopkins Health System nor by JAMA Ophthalmology.

 


PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with early intervention in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) without center-involved macular edema, which can have a profound impact on vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to nAMD, DME and DR management through utilization of clinical trial data, guideline-based treatment approaches and patient-specific factors – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that early vs delayed intervention can have on vision-related quality of life.
  • You will also be immersed in dynamic animations utilizing virtual reality and whiteboard platforms to memorably highlight key points related to how visual acuity is affected by intervention at different disease stages or treatment delay, as well as the impact of anti-vascular endothelial growth factor (anti-VEGF) therapy on the pathophysiologic defects associated with nAMD, DME and DR.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, and managed care professionals who manage patients with nAMD, DME, and DR in the absence of center-involved DME.


LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Evaluate clinical trial evidence on the optimization of monitoring, treatment dosing, and the association of early intervention on visual acuity outcomes in neovascular AMD (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) in the absence of center-involved DME
  • Assess the impact of treatments for nAMD, DME, and DR in the absence of center-involved DME on patients’ patient-reported vision-related quality of life
  • How to develop treatment plans for the management of nAMD, DME, and DR in the absence of center-involved DME that incorporate evidence from clinical trials, guideline recommendations, and patient-specific factors

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with nAMD, DME, and DR in the absence of center-involved DME.
Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Neil Bressler, MD receives grants to his institution for his research efforts from Bayer, Biogen, Novartis, Roche/Genentech, and Samsung Bioepis. He also serves as Chair of the National Eye Institute Data and Safety Monitoring Committee for Intramural Trials for the Emmes Company. He is also Editor in Chief of JAMA Ophthalmology.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse.
The reviewer has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Coordinator, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the enduring activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

RELEASE DATE: February 19, 2021

EXPIRATION DATE: February 19, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
27
Mon
Saving Sight in AMD: Key Concepts in Pathogenesis, Treatment Options and Management
Jul 27 2020 @ 12:00 am – Jul 27 2021 @ 11:45 pm

Saving Sight in AMD: Key Concepts in Pathogenesis, Treatment Options and Management

 

VIEW ACTIVITY

FACULTY

Steven Ferrucci, OD, FAAO
Chief of Optometry
Sepulveda VA Medical Center, Los Angeles, CA
Professor
Southern California College of Optometry at Marshall B. Ketchum University Fullerton, CA

PROGRAM OVERVIEW

This online activity is focused on the management of patients with age-related macular degeneration (AMD).

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in patients who have or are at risk for developing AMD
  • Describe the progressive visual changes that can be experienced by those who have or are at risk for and those that have been treated for AMD, thereby emphasizing the importance of proper eye care
  • Establish collaborative strategies that promote team-based communication and patient continuity of care to provide appropriate eye care delivery for patients who have or are at risk for developing AMD
  • Define the pathogenic changes observed with AMD which would be best managed by team-based approaches for appropriate eye care delivery
  • Evaluate the efficacy and safety of currently available treatments, including agents that target the VEGF pathway, used to manage patients with AMD

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based live activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.
Credits: 1.0 ANCC Contact Hour

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Steven Ferrucci, OD, FAAO, is on the speakers’ bureau/advisory board member for Alcon, CenterVue, Genentech, MacuLogix, Optovue, Regeneron, ScienceBased Health, and Visible Genomics.

Staff, Planners, and Managers
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests.

CME Content Review
The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse. The reviewer has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: July 27, 2020

EXPIRATION DATE: July 27, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

VIEW ACTIVITY

Jul
30
Thu
No Eyes Left Behind: Diabetic Retinopathy Clinical Essentials Related to Prevalence and Risk, Pathobiology, Detection and Treatment
Jul 30 2020 @ 12:00 am – Jul 30 2021 @ 11:45 pm

No Eyes Left Behind: Diabetic Retinopathy
Clinical Essentials Related to Prevalence and Risk, Pathobiology, Detection and Treatment

VIEW ACTIVITY

FACULTY

A. Paul Chous, MA, OD, FAAO
Chief of Optometry
Chous Eye Care Associates
Tacoma, WA
Adjunct Instructor
Nova Southeastern University College of Optometry
Optometrist and Diabetes Educator
Chous Eye Care Associates
Tacoma, WA

PROGRAM OVERVIEW

This online activity is focused on the management of patients with diabetic retinopathy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in patients who have or are at risk for developing diabetic retinopathy (DR)
  • Describe the progressive visual changes that can be experienced by those who have or are at risk for and those who have been treated for DR, thereby emphasizing the importance of proper eye care
  • Establish collaborative strategies that promote team-based communication and patient continuity of care to provide appropriate eye-care delivery for patients who have or are at risk for developing DR
  • Define the pathogenic changes observed with DR that would be best managed by team-based approaches for appropriate eye-care delivery
  • Evaluate the efficacy and safety of currently available treatments, including panretinal photocoagulation (PRP) and agents that target the VEGF pathway, used to manage patients with DR

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based live activity for a maximum of 1.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the web-based live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with DR.
Credits: 1.25 ANCC Contact Hour(s).

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

A.Paul Chous, MA, OD, FAAO, has received royalties and consulting fees from EyePromise. He is on the speaker’s bureaus for EyePromise, Regeneron, Genentech, and Zeiss. Dr. Chous has received fees for Non-CME/CE Services Received Directly from Regeneron and Genentech.

Staff, Planners, and Managers
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse. The reviewer has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Melissa Johnson, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: July 30, 2020

EXPIRATION DATE: July 30, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

VIEW ACTIVITY

Aug
28
Fri
AMD 2020: Best Practices for Current Management and Future Directions
Aug 28 2020 @ 5:45 pm – Aug 28 2021 @ 6:45 pm

AMD 2020: Best Practices for Current Management and Future Directions

FACULTY


Allen C. Ho, MD, FACS
Wills Eye Hospital Attending Surgeon and Director of Retina Research
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlanta Retina

PROGRAM OVERVIEW

This online activity is focused on management of patients with age-related macular degeneration.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in AMD patients
  • Describe progressive visual changes experienced by AMD patients
  • Establish collaborative strategies that promote team-based communication and patient continuity of care
  • Define the pathogenic changes observed with AMD
  • Evaluate the efficacy and safety of currently available anti-VEGF AMD treatments and potential future treatments in clinical development

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.

Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Allen Ho discloses the following:
– He is a consultant/advisor for Adverum, Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, Asclepix, Beaver-Visitec International, BioTime, Chengdu Kanghong Biotechnology, Genentech, Graybug, Gyroscope, IRIDEX, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, Notal, ONL, Optovue, PanOptica, Regeneron and RegenXBio.
– He has received grants from Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, BioTime, Chengdu Kanghong Biotechnology, Genetech, Gemini, Graybug, Gyroscope, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, Lumithera, National Eye Institute, Novartis, Optovue, ProQR, Regeneron, RegenXBio and Sanofi.
– He has ownership in Covalent Medical, ONL and PanOptica.

The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff Planners and Managers
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit
participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: August 28, 2020

EXPIRATION DATE: August 28, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

 

 

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

Jun
23
Wed
AMD Grand Rounds (Speaker: David Brown, MD)
Jun 23 @ 3:00 pm – 4:00 pm

Confirmed Date
Wednesday, June 23

Time
3:00 – 4:00 PM ET

Location
Age Related Macular Degeneration Grand Rounds

Confirmed Speaker
David Brown, MD

Jun
30
Wed
Prescott, AZ (Speaker: David Brown, MD)
Jun 30 @ 11:00 am – 12:00 pm

Confirmed Date
Wednesday, June 30

Time
11:00 – 12:00 PM EDT

Location
Age Related Macular Degeneration Grand Rounds
Prescott, AZ

Confirmed Speaker
David Brown, MD

Jul
23
Fri
Saginaw, MI (Speaker: David Brown, MD)
Jul 23 @ 8:00 am – 9:00 am

Confirmed Date
Friday, July 23

Time
8:00 – 9:00 AM EDT

Location
Age Related Macular Degeneration Grand Rounds
Saginaw, MI

Confirmed Speaker
David Brown, MD

A Virtual Reality Learning Experience: Integrating GLP-1 Receptor Agonists into T2DM Practice—Why, When, and How

Jul
25
Sat
Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention
Jul 25 2020 @ 1:00 am – Feb 19 2022 @ 2:00 am

Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention

View Activity

FACULTY

Neil M. Bressler, MD
James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

Participation by Dr. Neil Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the
Johns Hopkins Hospital, or the Johns Hopkins Health System nor by JAMA Ophthalmology.

 


PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with early intervention in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) without center-involved macular edema, which can have a profound impact on vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to nAMD, DME and DR management through utilization of clinical trial data, guideline-based treatment approaches and patient-specific factors – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that early vs delayed intervention can have on vision-related quality of life.
  • You will also be immersed in dynamic animations utilizing virtual reality and whiteboard platforms to memorably highlight key points related to how visual acuity is affected by intervention at different disease stages or treatment delay, as well as the impact of anti-vascular endothelial growth factor (anti-VEGF) therapy on the pathophysiologic defects associated with nAMD, DME and DR.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, and managed care professionals who manage patients with nAMD, DME, and DR in the absence of center-involved DME.


LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Evaluate clinical trial evidence on the optimization of monitoring, treatment dosing, and the association of early intervention on visual acuity outcomes in neovascular AMD (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) in the absence of center-involved DME
  • Assess the impact of treatments for nAMD, DME, and DR in the absence of center-involved DME on patients’ patient-reported vision-related quality of life
  • How to develop treatment plans for the management of nAMD, DME, and DR in the absence of center-involved DME that incorporate evidence from clinical trials, guideline recommendations, and patient-specific factors

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with nAMD, DME, and DR in the absence of center-involved DME.
Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Neil Bressler, MD receives grants to his institution for his research efforts from Bayer, Biogen, Novartis, Roche/Genentech, and Samsung Bioepis. He also serves as Chair of the National Eye Institute Data and Safety Monitoring Committee for Intramural Trials for the Emmes Company. He is also Editor in Chief of JAMA Ophthalmology.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse.
The reviewer has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Coordinator, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the enduring activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

RELEASE DATE: February 19, 2021

EXPIRATION DATE: February 19, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
27
Mon
Saving Sight in AMD: Key Concepts in Pathogenesis, Treatment Options and Management
Jul 27 2020 @ 12:00 am – Jul 27 2021 @ 11:45 pm

Saving Sight in AMD: Key Concepts in Pathogenesis, Treatment Options and Management

 

VIEW ACTIVITY

FACULTY

Steven Ferrucci, OD, FAAO
Chief of Optometry
Sepulveda VA Medical Center, Los Angeles, CA
Professor
Southern California College of Optometry at Marshall B. Ketchum University Fullerton, CA

PROGRAM OVERVIEW

This online activity is focused on the management of patients with age-related macular degeneration (AMD).

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in patients who have or are at risk for developing AMD
  • Describe the progressive visual changes that can be experienced by those who have or are at risk for and those that have been treated for AMD, thereby emphasizing the importance of proper eye care
  • Establish collaborative strategies that promote team-based communication and patient continuity of care to provide appropriate eye care delivery for patients who have or are at risk for developing AMD
  • Define the pathogenic changes observed with AMD which would be best managed by team-based approaches for appropriate eye care delivery
  • Evaluate the efficacy and safety of currently available treatments, including agents that target the VEGF pathway, used to manage patients with AMD

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based live activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.
Credits: 1.0 ANCC Contact Hour

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Steven Ferrucci, OD, FAAO, is on the speakers’ bureau/advisory board member for Alcon, CenterVue, Genentech, MacuLogix, Optovue, Regeneron, ScienceBased Health, and Visible Genomics.

Staff, Planners, and Managers
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests.

CME Content Review
The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse. The reviewer has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: July 27, 2020

EXPIRATION DATE: July 27, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

VIEW ACTIVITY

Jul
30
Thu
No Eyes Left Behind: Diabetic Retinopathy Clinical Essentials Related to Prevalence and Risk, Pathobiology, Detection and Treatment
Jul 30 2020 @ 12:00 am – Jul 30 2021 @ 11:45 pm

No Eyes Left Behind: Diabetic Retinopathy
Clinical Essentials Related to Prevalence and Risk, Pathobiology, Detection and Treatment

VIEW ACTIVITY

FACULTY

A. Paul Chous, MA, OD, FAAO
Chief of Optometry
Chous Eye Care Associates
Tacoma, WA
Adjunct Instructor
Nova Southeastern University College of Optometry
Optometrist and Diabetes Educator
Chous Eye Care Associates
Tacoma, WA

PROGRAM OVERVIEW

This online activity is focused on the management of patients with diabetic retinopathy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in patients who have or are at risk for developing diabetic retinopathy (DR)
  • Describe the progressive visual changes that can be experienced by those who have or are at risk for and those who have been treated for DR, thereby emphasizing the importance of proper eye care
  • Establish collaborative strategies that promote team-based communication and patient continuity of care to provide appropriate eye-care delivery for patients who have or are at risk for developing DR
  • Define the pathogenic changes observed with DR that would be best managed by team-based approaches for appropriate eye-care delivery
  • Evaluate the efficacy and safety of currently available treatments, including panretinal photocoagulation (PRP) and agents that target the VEGF pathway, used to manage patients with DR

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based live activity for a maximum of 1.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the web-based live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with DR.
Credits: 1.25 ANCC Contact Hour(s).

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

A.Paul Chous, MA, OD, FAAO, has received royalties and consulting fees from EyePromise. He is on the speaker’s bureaus for EyePromise, Regeneron, Genentech, and Zeiss. Dr. Chous has received fees for Non-CME/CE Services Received Directly from Regeneron and Genentech.

Staff, Planners, and Managers
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse. The reviewer has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Melissa Johnson, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: July 30, 2020

EXPIRATION DATE: July 30, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

VIEW ACTIVITY

Aug
28
Fri
AMD 2020: Best Practices for Current Management and Future Directions
Aug 28 2020 @ 5:45 pm – Aug 28 2021 @ 6:45 pm

AMD 2020: Best Practices for Current Management and Future Directions

FACULTY


Allen C. Ho, MD, FACS
Wills Eye Hospital Attending Surgeon and Director of Retina Research
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlanta Retina

PROGRAM OVERVIEW

This online activity is focused on management of patients with age-related macular degeneration.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in AMD patients
  • Describe progressive visual changes experienced by AMD patients
  • Establish collaborative strategies that promote team-based communication and patient continuity of care
  • Define the pathogenic changes observed with AMD
  • Evaluate the efficacy and safety of currently available anti-VEGF AMD treatments and potential future treatments in clinical development

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.

Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Allen Ho discloses the following:
– He is a consultant/advisor for Adverum, Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, Asclepix, Beaver-Visitec International, BioTime, Chengdu Kanghong Biotechnology, Genentech, Graybug, Gyroscope, IRIDEX, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, Notal, ONL, Optovue, PanOptica, Regeneron and RegenXBio.
– He has received grants from Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, BioTime, Chengdu Kanghong Biotechnology, Genetech, Gemini, Graybug, Gyroscope, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, Lumithera, National Eye Institute, Novartis, Optovue, ProQR, Regeneron, RegenXBio and Sanofi.
– He has ownership in Covalent Medical, ONL and PanOptica.

The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff Planners and Managers
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit
participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: August 28, 2020

EXPIRATION DATE: August 28, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

 

 

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

Jun
23
Wed
AMD Grand Rounds (Speaker: David Brown, MD)
Jun 23 @ 3:00 pm – 4:00 pm

Confirmed Date
Wednesday, June 23

Time
3:00 – 4:00 PM ET

Location
Age Related Macular Degeneration Grand Rounds

Confirmed Speaker
David Brown, MD

Jun
30
Wed
Prescott, AZ (Speaker: David Brown, MD)
Jun 30 @ 11:00 am – 12:00 pm

Confirmed Date
Wednesday, June 30

Time
11:00 – 12:00 PM EDT

Location
Age Related Macular Degeneration Grand Rounds
Prescott, AZ

Confirmed Speaker
David Brown, MD

Jul
23
Fri
Saginaw, MI (Speaker: David Brown, MD)
Jul 23 @ 8:00 am – 9:00 am

Confirmed Date
Friday, July 23

Time
8:00 – 9:00 AM EDT

Location
Age Related Macular Degeneration Grand Rounds
Saginaw, MI

Confirmed Speaker
David Brown, MD

Jul
25
Sat
Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention
Jul 25 2020 @ 1:00 am – Feb 19 2022 @ 2:00 am

Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention

View Activity

FACULTY

Neil M. Bressler, MD
James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

Participation by Dr. Neil Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the
Johns Hopkins Hospital, or the Johns Hopkins Health System nor by JAMA Ophthalmology.

 


PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with early intervention in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) without center-involved macular edema, which can have a profound impact on vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to nAMD, DME and DR management through utilization of clinical trial data, guideline-based treatment approaches and patient-specific factors – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that early vs delayed intervention can have on vision-related quality of life.
  • You will also be immersed in dynamic animations utilizing virtual reality and whiteboard platforms to memorably highlight key points related to how visual acuity is affected by intervention at different disease stages or treatment delay, as well as the impact of anti-vascular endothelial growth factor (anti-VEGF) therapy on the pathophysiologic defects associated with nAMD, DME and DR.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, and managed care professionals who manage patients with nAMD, DME, and DR in the absence of center-involved DME.


LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Evaluate clinical trial evidence on the optimization of monitoring, treatment dosing, and the association of early intervention on visual acuity outcomes in neovascular AMD (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) in the absence of center-involved DME
  • Assess the impact of treatments for nAMD, DME, and DR in the absence of center-involved DME on patients’ patient-reported vision-related quality of life
  • How to develop treatment plans for the management of nAMD, DME, and DR in the absence of center-involved DME that incorporate evidence from clinical trials, guideline recommendations, and patient-specific factors

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with nAMD, DME, and DR in the absence of center-involved DME.
Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Neil Bressler, MD receives grants to his institution for his research efforts from Bayer, Biogen, Novartis, Roche/Genentech, and Samsung Bioepis. He also serves as Chair of the National Eye Institute Data and Safety Monitoring Committee for Intramural Trials for the Emmes Company. He is also Editor in Chief of JAMA Ophthalmology.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse.
The reviewer has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Coordinator, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the enduring activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

RELEASE DATE: February 19, 2021

EXPIRATION DATE: February 19, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
27
Mon
Saving Sight in AMD: Key Concepts in Pathogenesis, Treatment Options and Management
Jul 27 2020 @ 12:00 am – Jul 27 2021 @ 11:45 pm

Saving Sight in AMD: Key Concepts in Pathogenesis, Treatment Options and Management

 

VIEW ACTIVITY

FACULTY

Steven Ferrucci, OD, FAAO
Chief of Optometry
Sepulveda VA Medical Center, Los Angeles, CA
Professor
Southern California College of Optometry at Marshall B. Ketchum University Fullerton, CA

PROGRAM OVERVIEW

This online activity is focused on the management of patients with age-related macular degeneration (AMD).

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in patients who have or are at risk for developing AMD
  • Describe the progressive visual changes that can be experienced by those who have or are at risk for and those that have been treated for AMD, thereby emphasizing the importance of proper eye care
  • Establish collaborative strategies that promote team-based communication and patient continuity of care to provide appropriate eye care delivery for patients who have or are at risk for developing AMD
  • Define the pathogenic changes observed with AMD which would be best managed by team-based approaches for appropriate eye care delivery
  • Evaluate the efficacy and safety of currently available treatments, including agents that target the VEGF pathway, used to manage patients with AMD

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based live activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.
Credits: 1.0 ANCC Contact Hour

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Steven Ferrucci, OD, FAAO, is on the speakers’ bureau/advisory board member for Alcon, CenterVue, Genentech, MacuLogix, Optovue, Regeneron, ScienceBased Health, and Visible Genomics.

Staff, Planners, and Managers
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests.

CME Content Review
The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse. The reviewer has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: July 27, 2020

EXPIRATION DATE: July 27, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

VIEW ACTIVITY

Jul
30
Thu
No Eyes Left Behind: Diabetic Retinopathy Clinical Essentials Related to Prevalence and Risk, Pathobiology, Detection and Treatment
Jul 30 2020 @ 12:00 am – Jul 30 2021 @ 11:45 pm

No Eyes Left Behind: Diabetic Retinopathy
Clinical Essentials Related to Prevalence and Risk, Pathobiology, Detection and Treatment

VIEW ACTIVITY

FACULTY

A. Paul Chous, MA, OD, FAAO
Chief of Optometry
Chous Eye Care Associates
Tacoma, WA
Adjunct Instructor
Nova Southeastern University College of Optometry
Optometrist and Diabetes Educator
Chous Eye Care Associates
Tacoma, WA

PROGRAM OVERVIEW

This online activity is focused on the management of patients with diabetic retinopathy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in patients who have or are at risk for developing diabetic retinopathy (DR)
  • Describe the progressive visual changes that can be experienced by those who have or are at risk for and those who have been treated for DR, thereby emphasizing the importance of proper eye care
  • Establish collaborative strategies that promote team-based communication and patient continuity of care to provide appropriate eye-care delivery for patients who have or are at risk for developing DR
  • Define the pathogenic changes observed with DR that would be best managed by team-based approaches for appropriate eye-care delivery
  • Evaluate the efficacy and safety of currently available treatments, including panretinal photocoagulation (PRP) and agents that target the VEGF pathway, used to manage patients with DR

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based live activity for a maximum of 1.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the web-based live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with DR.
Credits: 1.25 ANCC Contact Hour(s).

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

A.Paul Chous, MA, OD, FAAO, has received royalties and consulting fees from EyePromise. He is on the speaker’s bureaus for EyePromise, Regeneron, Genentech, and Zeiss. Dr. Chous has received fees for Non-CME/CE Services Received Directly from Regeneron and Genentech.

Staff, Planners, and Managers
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse. The reviewer has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Melissa Johnson, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: July 30, 2020

EXPIRATION DATE: July 30, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

VIEW ACTIVITY

Aug
28
Fri
AMD 2020: Best Practices for Current Management and Future Directions
Aug 28 2020 @ 5:45 pm – Aug 28 2021 @ 6:45 pm

AMD 2020: Best Practices for Current Management and Future Directions

FACULTY


Allen C. Ho, MD, FACS
Wills Eye Hospital Attending Surgeon and Director of Retina Research
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlanta Retina

PROGRAM OVERVIEW

This online activity is focused on management of patients with age-related macular degeneration.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and optometrists who manage patients with DR, DME, and AMD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the importance of proper eye care in AMD patients
  • Describe progressive visual changes experienced by AMD patients
  • Establish collaborative strategies that promote team-based communication and patient continuity of care
  • Define the pathogenic changes observed with AMD
  • Evaluate the efficacy and safety of currently available anti-VEGF AMD treatments and potential future treatments in clinical development

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AMD.

Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Allen Ho discloses the following:
– He is a consultant/advisor for Adverum, Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, Asclepix, Beaver-Visitec International, BioTime, Chengdu Kanghong Biotechnology, Genentech, Graybug, Gyroscope, IRIDEX, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, Notal, ONL, Optovue, PanOptica, Regeneron and RegenXBio.
– He has received grants from Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, BioTime, Chengdu Kanghong Biotechnology, Genetech, Gemini, Graybug, Gyroscope, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, Lumithera, National Eye Institute, Novartis, Optovue, ProQR, Regeneron, RegenXBio and Sanofi.
– He has ownership in Covalent Medical, ONL and PanOptica.

The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff Planners and Managers
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit
participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: August 28, 2020

EXPIRATION DATE: August 28, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

 

 

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

Jun
23
Wed
AMD Grand Rounds (Speaker: David Brown, MD)
Jun 23 @ 3:00 pm – 4:00 pm

Confirmed Date
Wednesday, June 23

Time
3:00 – 4:00 PM ET

Location
Age Related Macular Degeneration Grand Rounds

Confirmed Speaker
David Brown, MD

Jun
30
Wed
Prescott, AZ (Speaker: David Brown, MD)
Jun 30 @ 11:00 am – 12:00 pm

Confirmed Date
Wednesday, June 30

Time
11:00 – 12:00 PM EDT

Location
Age Related Macular Degeneration Grand Rounds
Prescott, AZ

Confirmed Speaker
David Brown, MD

Jul
23
Fri
Saginaw, MI (Speaker: David Brown, MD)
Jul 23 @ 8:00 am – 9:00 am

Confirmed Date
Friday, July 23

Time
8:00 – 9:00 AM EDT

Location
Age Related Macular Degeneration Grand Rounds
Saginaw, MI

Confirmed Speaker
David Brown, MD

Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Clinician Scientific & Educational Resources

The RELIEF Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for age-related macular degeneration (AMD). Click on one of the options below to learn more about AMD.

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM). This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2019 | AMD Relief | All Rights Reserved | Website by Divigner

Scientific Council

Neil M. Bressler, MD

James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

A. Paul Chous, MA, OD, FAAO

Specializing in Diabetes Eye Care & Education, Chous Eye Care Associates
Adjunct Professor of Optometry, Western University of Health Sciences
AOA Representative, National Diabetes Education Program
Tacoma, WA

Steven Ferrucci, OD, FAAO

Chief of Optometry, Sepulveda VA Medical Center
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Sepulveda, CA

Julia A. Haller, MD

Ophthalmologist-in-Chief
Wills Eye Hospital
Philadelphia, PA

Allen C. Ho, MD, FACS

Director, Retina Research
Wills Eye Hospital
Professor and Chair of the Department of Ophthalmology
Thomas Jefferson University Hospitals
Philadelphia, PA

Charles C. Wykoff, MD, PhD

Director of Research, Retina Consultants of Houston
Associate Professor of Clinical Ophthalmology
Blanton Eye Institute & Houston Methodist Hospital
Houston, TX